Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

Lilly plans to file Foundayo with the FDA for type 2 diabetes by end of Q2 after the ACHIEVE-4 trial met its primary ...

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...

The results seen with Foundayo, also known as orforglipron, enabled Lilly’s late-stage Achieve-4 study to hit its primary ...

"Lilly debuts more Foundayo data as FDA requests post-marketing trials" was originally created and published by ...

FDA required additional post-approval evaluation of myocardial infarction, stroke, and other cardiovascular events because ...

Shares of LifeMD rose after the telehealth company said it is offering Eli Lilly's GLP-1 obesity pill, Foundayo, through its weight management program. Shares were up 12% to $4.59 on Monday. The stock ...

The pharmaceutical’s Foundayo drug takes on oral Wegovy, the popular treatment from Novo Nordisk.

Even as Eli Lilly gets underway with its next major obesity launch in Foundayo, an FDA document related to the oral treatment ...

While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital ...

Eli Lilly (NYSE:LLY) reported positive phase 3 ACHIEVE-4 results for its once-daily oral GLP-1 therapy Foundayo (orforglipron ...